Beneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC

References

• Solowij N, Pesa N. Cannabis and cognition: short-and long-term effects. In: Castle D, Murray RM, D’Souza DC, editors. Marijuana and madness. Cambridge: Cambridge University Press; 2011. p. 91–102.
   Google Scholar
• Zuurman L, Ippel AE, Moin E, Jma: VG. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol. 2009;67(1):5–21. doi:10.1111/j.1365-2125.2008.03329.x.
   PubMed Web of Science ®Google Scholar
• Sagar KA, Gruber SA. Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. Int Rev Psychiatry. 2018;30(3):251–67. doi:10.1080/09540261.2018.1460334.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nature Rev Drug Discov. 2004;3(9):771–84. doi:10.1038/nrd1495.
   PubMed Web of Science ®Google Scholar
• Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Ann Med. 2016;48(3):128–41. doi:10.3109/07853890.2016.1145794.
   PubMed Web of Science ®Google Scholar
• Giacoppo S, Mandolino G, Galuppo M, Bramanti P, Mazzon E. Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules. 2014;19(11):18781–816. doi:10.3390/molecules191118781.
   PubMed Web of Science ®Google Scholar
• Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462. doi:10.1124/pr.58.3.2.
   PubMed Web of Science ®Google Scholar
• Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89(1):309–80. doi:10.1152/physrev.00019.2008.
   PubMed Web of Science ®Google Scholar
• Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998;352(9140):1611–16. doi:10.1016/S0140-6736(98)05021-1.
   PubMed Web of Science ®Google Scholar
• Iversen L. Cannabis and the brain. Brain. 2003;126:1252–70.
   PubMed Web of Science ®Google Scholar
• Solowij N, Pesa N. Cognitive abnormalities and cannabis use. Rev Bras Psiquiatr. 2010;32:S31–S40.
   PubMed Web of Science ®Google Scholar
• Egerton A, Allison C, Brett RR, Pratt JA. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev. 2006;30(5):680–95. doi:10.1016/j.neubiorev.2005.12.002.
   PubMed Web of Science ®Google Scholar
• Pattij T, Wiskerke J, Schoffelmeer ANM. Cannabinoid modulation of executive functions. Eur J Pharmacol. 2008;585(2–3):458–63. doi:10.1016/j.ejphar.2008.02.099.
   PubMed Web of Science ®Google Scholar
• Solowij N, Michie PT. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci. 2007;32(1):30–52.
   PubMed Web of Science ®Google Scholar
• Solowij N, Grenyer BFS. Are the adverse consequences of cannabis use age-dependent? Addiction. 2002;97(9):1083–86.
   PubMed Web of Science ®Google Scholar
• Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology (Berl). 2006;185(3):358–68. doi:10.1007/s00213-005-0298-7.
   PubMed Web of Science ®Google Scholar
• Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology (Berl). 2004;176(3–4):239–47. doi:10.1007/s00213-004-1885-8.
   PubMed Web of Science ®Google Scholar
• Cohen M, Rasser PE, Peck G, Carr VJ, Ward PB, Thompson PM, Johnston P, Baker A, Schall U. Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int J Neuropsychopharmacol. 2011;15(3):1–11.
   Web of Science ®Google Scholar
• Solowij N, Yucel M, Respondek C, Whittle S, Lindsay E, Pantelis C, Lubman DI. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol Med. 2011;41(11):2349–59. doi:10.1017/S003329171100050X.
   PubMed Web of Science ®Google Scholar
• Fehr KA, Kalant H, LeBlanc AE. Residual learning deficit after heavy exposure to cannabis or alcohol in rats. Science. 1976;192(4245):1249–51.
   PubMed Web of Science ®Google Scholar
• Stiglick A, Kalant H. Behavioral effects of prolonged administration of delta 9-tetrahydrocannabinol in the rat. Psychopharmacology (Berl). 1983;80(4):325–30.
   PubMed Web of Science ®Google Scholar
• Rubino T, Realini N, Braida D, Guidi S, Capurro V, Vigano D, Guidali C, Pinter M, Sala M, Bartesaghi R, et al. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus. 2009;19(8):763–72. doi:10.1002/hipo.20554.
   PubMed Web of Science ®Google Scholar
• Lawston J, Borella A, Robinson JK, Whitaker-Azmitia PM. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res. 2000;877(2):407–10.
   PubMed Web of Science ®Google Scholar
• Scallet AC. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav. 1991;40(3):671–76.
   PubMed Web of Science ®Google Scholar
• Scallet AC, Uemura E, Andrews A, Ali SF, McMillan DE, Paule MG, Brown RM, Slikker W Jr. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res. 1987;436(1):193–98.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Galve-Roperh I, Rueda D, Guzman M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol. 1998;54(5):834–43.
   PubMed Web of Science ®Google Scholar
• Chan GCK, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of Delta(9)-tetrahydrocannabinol. J Neurosci. 1998;18(14):5322–32.
   PubMed Web of Science ®Google Scholar
• Del Pulgar TG, Velasco G, Sanchez C, Haro A, Guzman M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J. 2002;363:183–188.
   PubMed Web of Science ®Google Scholar
• Downer EJ, Fogarty MP, Campbell VA. Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br J Pharmacol. 2003;140(3):547–57. doi:10.1038/sj.bjp.0705464.
   PubMed Web of Science ®Google Scholar
• Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999;19(8):2987–95.
   PubMed Web of Science ®Google Scholar
• van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci. 2001a;21(17):6475–79. doi:10.1523/JNEUROSCI.21-17-06475.2001.
   PubMed Web of Science ®Google Scholar
• van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, Veldink GA, Vliegenthart JF, Di Marzo V, Nicolay K. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci. 2001b;21(22):8765–71. doi:10.1523/JNEUROSCI.21-22-08765.2001.
   PubMed Web of Science ®Google Scholar
• Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001;413(6855):527–31. doi:10.1038/35097089.
   PubMed Web of Science ®Google Scholar
• Tourino C, Zimmer A, Valverde O. THC prevents MDMA neurotoxicity in mice. PLoS One. 2010;5(2):e9143. doi:10.1371/journal.pone.0009143.
   PubMed Web of Science ®Google Scholar
• Shouman B, Fontaine RH, Baud O, Schwendimann L, Keller M, Spedding M, Lelievre V, Gressens P. Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. Br J Pharmacol. 2006;148(4):442–51. doi:10.1038/sj.bjp.0706755.
   PubMed Web of Science ®Google Scholar
• Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A. 1992;89(9):3825–29.
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in Ng108-15 neuroblastoma-cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol. 1992;106(2):231–32.
   PubMed Web of Science ®Google Scholar
• Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci. 1996;16(14):4322–34.
   PubMed Web of Science ®Google Scholar
• Hillard CJ, Muthian S, Kearn CS. Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. 1999;459(2):277–81.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia. 2003;41(2):161–68. doi:10.1002/glia.10177.
   PubMed Web of Science ®Google Scholar
• Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke. 2003;34(8):2000–06. doi:10.1161/01.STR.0000079817.68944.1E.
   PubMed Web of Science ®Google Scholar
• Wagner JA, Jarai Z, Batkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol. 2001;423(2–3):203–10.
   PubMed Web of Science ®Google Scholar
• Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta(9)-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998;95(14):8268–73.
   PubMed Web of Science ®Google Scholar
• Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HHO, Fernandez-Ruiz JJ, Hansen HS. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem. 2001;78(6):1415–27.
   PubMed Web of Science ®Google Scholar
• Bilkei-Gorzo A. The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3326–41. doi:10.1098/rstb.2011.0388.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Stella N, Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nature Rev Neurosci. 2015;16(1):30–42. doi:10.1038/nrn3876.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med. 2002;8(2):58–61.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz J, Gomez-Ruiz M, Garcia C, Hernandez M, Ramos JA. Modeling neurodegenerative disorders for developing cannabinoid-based neuroprotective therapies. Methods Enzymol. 2017;593:175–198. doi:10.1016/bs.mie.2017/06/021.
   Google Scholar
• Milton NGN. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett. 2002;332(2):127–30.
   PubMed Web of Science ®Google Scholar
• Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis. 2005;19(1–2):96–107. doi:10.1016/j.nbd.2004.11.009.
   PubMed Web of Science ®Google Scholar
• Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernandez-Ruiz J, Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport. 2004;15(15):2375–79.
   PubMed Web of Science ®Google Scholar
• Ramirez BG, Blazquez C, Del Pulgar TG, Guzman N, Mal: DC. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005;25(8):1904–13. doi:10.1523/JNEUROSCI.4540-04.2005.
   PubMed Web of Science ®Google Scholar
• Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012;9:8. doi:10.1186/1742-2094-9-8.
   PubMed Web of Science ®Google Scholar
• Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. Mol Cell Neurosci. 2013;56:255–262. doi:10.1016/j.mcn.2013.06.004.
   PubMed Web of Science ®Google Scholar
• Aso E, Sanchez-Plac A, Vegas-Lozano E, Maldonado R, Ferrer I. Cannabis-based medicine reduces multiple pathological processes in A beta PP/PS1 mice. J Alzheimers Dis. 2015;43(3):977–91. doi:10.3233/JAD-141014.
   PubMed Web of Science ®Google Scholar
• Marchalant Y, Cerbai F, Brothers HM, Wenk GL. Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiol Aging. 2008;29(12):1894–901. doi:10.1016/j.neurobiolaging.2007.04.028.
   PubMed Web of Science ®Google Scholar
• Bilkei-Gorzo A, Albayram O, Draffehn A, Michel K, Piyanova A, Oppenheimer H, Dvir-Ginzberg M, Racz I, Ulas T, Imbeault S, et al. A chronic low dose of [Delta]9-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat Med. 2017;23(6):782–87. doi:10.1038/nm.4311.
   PubMed Web of Science ®Google Scholar
• Marchalant Y, Brothers HM, Wenk GL. Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain. Mol Psychiatry. 2009;14(12):1068–69. doi:10.1038/mp.2009.62.
   PubMed Web of Science ®Google Scholar
• Li Y, Kim J. Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus. Neuroscience. 2017;363:11–25. doi:10.1016/j.neuroscience.2017.08.053.
   PubMed Web of Science ®Google Scholar
• Onaivi ES, Ishiguro H, Gu SZ, Liu QR. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol. 2012;26(1):92–103. doi:10.1177/0269881111400652.
   PubMed Web of Science ®Google Scholar
• Sierra S, Luquin N, Rico AJ, Gomez-Bautista V, Roda E, Dopeso-Reyes IG, Vazquez A, Martinez-Pinilla E, Labandeira-Garcia JL, Franco R, et al. Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct. 2015;220(5):2721–38. doi:10.1007/s00429-014-0823-8.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Gao M, Shen H, Bi GH, Yang HJ, Liu QR, Wu J, Gardner EL, Bonci A, Xi ZX. Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats. Addict Biol. 2017;22(3):752–65. doi:10.1111/adb.12367.
   PubMed Web of Science ®Google Scholar
• Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha(2)-adrenoceptor agonist and moderately potent 5HT(1A) receptor antagonist. Br J Pharmacol. 2010;159(1):129–41. doi:10.1111/j.1476-5381.2009.00515.x.
   PubMed Web of Science ®Google Scholar
• Console-Bram L, Brailoiu E, Brailoiu GC, Sharir H, Abood ME. Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol. 2014;171(16):3908–17. doi:10.1111/bph.12746.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Di Marzo V. Non-CB1, non-CB2 Receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharm. 2010;5(1):103–21. doi:10.1007/s11481-009-9177-z.
   PubMed Web of Science ®Google Scholar
• Sterin-Borda L, Del Zar CF, Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem Pharmacol. 2005;69(12):1705–13. doi:10.1016/j.bcp.2005.03.027.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Howlett AC. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol. 2005;67(6):2016–24. doi:10.1124/mol.104.003558.
   PubMed Web of Science ®Google Scholar
• Roloff AM, Thayer SA. Modulation of excitatory synaptic transmission by Delta(9)-Tetrahydrocannabinol switches from agonist to antagonist depending on firing rate. Mol Pharmacol. 2009;75(4):892–900. doi:10.1124/mol.108.051482.
   PubMed Web of Science ®Google Scholar
• Bologov A, Gafni M, Keren O, Sarne Y. Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro. Cell Mol Neurobiol. 2011;31(2):195–202. doi:10.1007/s10571-010-9604-y.
   PubMed Web of Science ®Google Scholar
• Downer EJ, Gowran A, Campbell VA. A comparison of the apoptotic effect of Delta(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res. 2007;1175:39–47. doi:10.1016/j.brainres.2007.07.076.
   PubMed Web of Science ®Google Scholar
• Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PCL, Lubman DI, Yucel M. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology. 2011;216(1):131–44. doi:10.1007/s00213-011-2203-x.
   PubMed Web of Science ®Google Scholar
• Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657–E2664. doi:10.1073/pnas.1206820109.
   PubMed Web of Science ®Google Scholar
• Tzavara ET, Wade M, Nomikos GG. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci. 2003;23(28):9374–84.
   PubMed Web of Science ®Google Scholar
• Norris C, Szkudlarek HJ, Pereira B, Laviolette SR. Delta9-tetrahydrocannabinol (THC) produces bi-phasic rewarding and avversive effects in the anterior vs. posterior nucleus accumbens shell through dissociable mu vs. kappa opiate receptor mechanisms and differential modulation of medium spiny neuron activity states. 28th Annual Symposium on the Cannabinoids. Leiden, Holland: International Cannabinoid Research Society, Research Triangle Park, NC, USA; 2018. p. 42.
   Google Scholar
• Bellocchio L, Lafenetre P, Cannich A, Cota D, Puente N, Grandes P, Chaouloff F, Piazza PV, Marsicano G. Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci. 2010;13(3):281–83. doi:10.1038/nn.2494.
   PubMed Web of Science ®Google Scholar
• Funada M, Takebayashi-Ohsawa M. Synthetic cannabinoid AM2201 induces seizures: involvement of cannabinoid CB1 receptors and glutamatergic transmission. Toxicol Appl Pharmacol. 2018;338:1–8. doi:10.1016/j.taap.2017.10.007.
   PubMed Web of Science ®Google Scholar
• Keren O, Sarne Y. Multiple mechanisms of CB1 cannabinoid receptors regulation. Brain Res. 2003;980(2):197–205.
   PubMed Web of Science ®Google Scholar
• Calabrese EJ. Hormetic mechanisms. Crit Rev Toxicol. 2013;43(7):580–606. doi:10.3109/10408444.2013.808172.
   PubMed Web of Science ®Google Scholar
• Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav. 1998;59(2):347–52.
   PubMed Web of Science ®Google Scholar
• Murray JE, Bevins RA. Cannabinoid conditioned reward and aversion: behavioral and neural processes. ACS Chem Neurosci. 2010;1(4):265–78. doi:10.1021/cn100005p.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kodaka T, Kondo S, Nakane S, Kondo H, Waku K, Ishima Y, Watanabe K, Yamamoto I. Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. J Biochem. 1997;122(4):890–95.
   PubMed Web of Science ®Google Scholar
• Rubovitch V, Gafni M, Sarne Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res. 2002;101(1–2):93–102.
   PubMedGoogle Scholar
• Bash R, Rubovitch V, Gafni M, Sarne Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals. 2003;12(1):39–44. doi:10.1159/000068915.
   PubMedGoogle Scholar
• Sarne Y, Keren O. Are cannabinoid drugs neurotoxic or neuroprotective? Med Hypotheses. 2004;63(2):187–92. doi:10.1016/j.mehy.2004.02.043.
   PubMed Web of Science ®Google Scholar
• Amal H, Fridman-Rozevich L, Senn R, Strelnikov A, Gafni M, Keren O, Sarne Y. Long-term consequences of a single treatment of mice with an ultra-low dose of Delta9-tetrahydrocannabinol (THC). Behav Brain Res. 2010;206(2):245–53. doi:10.1016/j.bbr.2009.09.021.
   PubMed Web of Science ®Google Scholar
• Senn R, Keren O, Hefetz A, Sarne Y. Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice. Pharmacol Biochem Behav. 2008;88(3):230–37. doi:10.1016/j.pbb.2007.08.005.
   PubMed Web of Science ®Google Scholar
• Tselnicker I, Keren O, Hefetz A, Pick CG, Sarne Y. A single low dose of tetrahydrocannabinol induces long-term cognitive deficits. Neurosci Lett. 2007;411(2):108–11. doi:10.1016/j.neulet.2006.10.033.
   PubMed Web of Science ®Google Scholar
• Tselnicker I. A single ultra-low dose of delta-9-tetrahydrocannabinol causes long-term cognitive dificits in mice [MSc. Thesis]. Tel-Aviv: Tel-Aviv university; 2005.
   Google Scholar
• Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26(5):248–54. doi:10.1016/S0166-2236(03)00071-7.
   PubMed Web of Science ®Google Scholar
• Kitagawa K, Matsumoto M, Kuwabara K, Tagaya M, Ohtsuki T, Hata R, Ueda H, Handa N, Kimura K, Kamada T. ‘Ischemic tolerance’ phenomenon detected in various brain regions. Brain Res. 1991;561(2):203–11.
   PubMed Web of Science ®Google Scholar
• Pignataro G, Scorziello A, Di Renzo G, Annunziato L. Post-ischemic brain damage: effect of ischemic preconditioning and postconditioning and identification of potential candidates for stroke therapy. FEBS J. 2009;276(1):46–57. doi:10.1111/j.1742-4658.2008.06769.x.
   PubMed Web of Science ®Google Scholar
• Zhao H. Ischemic postconditioning as a novel avenue to protect against brain injury after stroke. J Cereb Blood Flow Metab. 2009;29(5):873–85. doi:10.1038/jcbfm.2009.13.
   PubMed Web of Science ®Google Scholar
• Assaf F, Fishbein M, Gafni M, Keren O, Sarne Y. Pre- and post-conditioning treatment with an ultra-low dose of Delta9-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage. Behav Brain Res. 2011;220(1):194–201. doi:10.1016/j.bbr.2011.02.005.
   PubMed Web of Science ®Google Scholar
• Fishbein M, Gov S, Assaf F, Gafni M, Keren O, Sarne Y. Long-term behavioral and biochemical effects of an ultra-low dose of Delta9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling. Exp Brain Res. 2012;221(4):437–48. doi:10.1007/s00221-012-3186-5.
   PubMed Web of Science ®Google Scholar
• Fishbein-Kaminietsky M, Gafni M, Sarne Y. Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage. J Neurosci Res. 2014;92(12):1669–77. doi:10.1002/jnr.23452.
   PubMed Web of Science ®Google Scholar
• Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124–36.
   PubMed Web of Science ®Google Scholar
• Waldman M, Hochhauser E, Fishbein M, Aravot D, Shainberg A, Sarne Y. An ultra-low dose of tetrahydrocannabinol provides cardioprotection. Biochem Pharmacol. 2013;85(11):1626–33. doi:10.1016/j.bcp.2013.03.014.
   PubMed Web of Science ®Google Scholar
• Hochhauser E, Lahat E, Sultan M, Pappo O, Waldman M, Sarne Y, Shainberg A, Gutman M, Safran M, Ben Ari Z. Ultra low dose Delta 9-Tetrahydrocannabinol protects mouse liver from ischemia reperfusion injury. Cell Physiol Biochem. 2015;36(5):1971–81. doi:10.1159/000430165.
   PubMed Web of Science ®Google Scholar
• Sarne Y, Toledano R, Rachmany L, Sasson E, Doron R. Reversal of age-related cognitive impairments in mice by an extremely low dose of tetrahydrocannabinol. Neurobiol Aging. 2018;61:177–86. doi:10.1016/j.neurobiolaging.2017.09.025.
   PubMed Web of Science ®Google Scholar
• Albayram O, Bilkei-Gorzo A, Zimmer A. Loss of CB1 receptors leads to differential age-related changes in reward-driven learning and memory. Front Aging Neurosci. 2012;4:8.
   PubMed Web of Science ®Google Scholar
• Fasano S, Brambilla R. Ras-ERK signaling in behavior: old questions and new perspectives. Front Behav Neurosci. 2011;5:79.
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis. 2009;204(2):334–41. doi:10.1016/j.atherosclerosis.2008.10.029.
   PubMed Web of Science ®Google Scholar
• Jin RL, Li WB, Li QJ, Zhang M, Man XH, Sun XC, Zhao HG, Qi J. The role of extracellular signal-regulated kinases in the neuroprotection of limb ischernic preconditioning. Neurosci Res. 2006;55(1):65–73. doi:10.1016/j.neures.2006.01.006.
   PubMed Web of Science ®Google Scholar
• Cunha C, Brambilla R, Thomas KL. A simple role for BDNF in learning and memory? Front Mol Neurosci. 2010;3:1.
   PubMed Web of Science ®Google Scholar
• Lipsky RH, Marini AM. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci. 2007;1122:130–43. doi:10.1196/annals.1403.009.
   PubMed Web of Science ®Google Scholar
• Yin JC, Tully T. CREB and the formation of long-term memory. Curr Opin Neurobiol. 1996;6(2):264–68.
   PubMed Web of Science ®Google Scholar
• Lee HT, Chang YC, Wang LY, Wang ST, Huang CC, Ho CJ. cAMP response element-binding protein activation in ligation preconditioning in neonatal brain. Ann Neurol. 2004;56(5):611–23. doi:10.1002/ana.20259.
   PubMed Web of Science ®Google Scholar
• Lee TH, Yang JT, Ko YS, Kato H, Itoyama Y, Kogure K. Influence of ischemic preconditioning on levels of nerve growth factor, brain-derived neurotrophic factor and their high-affinity receptors in hippocampus following forebrain ischemia. Brain Res. 2008;1187:1–11. doi:10.1016/j.brainres.2007.09.078.
   PubMed Web of Science ®Google Scholar
• Lin WY, Chang YC, Lee HT, Huang CC. CREB activation in the rapid, intermediate, and delayed ischemic preconditioning against hypoxic-ischemia in neonatal rat. J Neurochem. 2009;108(4):847–59. doi:10.1111/j.0022-3042.2008.05828.x.
   PubMed Web of Science ®Google Scholar
• Truettner J, Busto R, Zhao WZ, Ginsberg MD, Perez-Pinzon MA. Effect of ischemic preconditioning on the expression of putative neuroprotective genes in the rat brain. Mol Brain Res. 2002;103(1–2):106–15.
   PubMedGoogle Scholar
• Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20(6):659–63. doi:10.1159/000430165.
   PubMed Web of Science ®Google Scholar
• Gao J, Wang WY, Mao YW, Graff J, Guan JS, Pan L, Mak G, Kim D, Su SC, Tsai LH. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature. 2010;466(7310):1105–U1120. doi:10.1038/nature09271.
   PubMed Web of Science ®Google Scholar
• Gueguen C, Palmier B, Plotkine M, Marchand-Leroux C, Bessson VC. Neurological and histological consequences induced by in vivo cerebral oxidative stress: evidence for beneficial effects of SRT1720, a Sirtuin 1 activator, and Sirtuin 1-mediated neuroprotective effects of poly(ADP-ribose) polymerase inhibition. PLoS One. 2014;9(2). doi:10.1371/journal.pone.0087367.
   Web of Science ®Google Scholar
• Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014;81(3):471–83. doi:10.1016/j.neuron.2014.01.028.
   PubMed Web of Science ®Google Scholar
• Michan S, Li Y, Chou MMH, Parrella E, Ge HY, Long JM, Allard JS, Lewis K, Miller M, Xu W, et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci. 2010;30(29):9695–707. doi:10.1523/JNEUROSCI.0027-10.2010.
   PubMed Web of Science ®Google Scholar
• Zhang XS, Wu Q, Wu LY, Ye ZN, Jiang TW, Li W, Zhuang Z, Zhou ML, Zhang X, Hang CH. Sirtuin 1 activation protects against early brain injury after experimental subarachnoid hemorrhage in rats. Cell Death Dis. 2016;7:1–12. doi:10.1038/cddis.2016.292.
   Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev Drug Discov. 2006;5(6):493–506. doi:10.1038/nrd2060.
   PubMed Web of Science ®Google Scholar
• Cristofol R, Porquet D, Corpas R, Coto-Montes A, Serret J, Camins A, Pallas M, Sanfeliu C. Neurons from senescence-accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. J Pineal Res. 2012;52(3):271–81. doi:10.1111/j.1600-079X.2011.00939.x.
   PubMed Web of Science ®Google Scholar
• Ramis MR, Esteban S, Miralles A, Tan DX, Reiter RJ. Caloric restriction, resveratrol and melatonin: role of SIRT1 and implications for aging and related-diseases. Mech Ageing Dev. 2015;146:28–41. doi:10.1016/j.mad.2015.03.008.
   PubMed Web of Science ®Google Scholar
• Koronowski KB, Dave KR, Saul I, Camarena V, Thompson JW, Neumann JT, Young JI, Perez-Pinzon MA. Resveratrol preconditioning induces a novel extended window of ischemic tolerance in the mouse brain. Stroke. 2015;46(8):2293–98. doi:10.1161/STROKEAHA.115.009876.
   PubMed Web of Science ®Google Scholar
• Morris BJ. Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med. 2013;56:133–171. doi:10.1016/j.freeradbiomed.2012.10.525.
   PubMed Web of Science ®Google Scholar
• DiNieri JA, Wang XY, Szutorisz H, Spano SM, Kaur J, Casaccia P, Dow-Edwards D, Hurd YL. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry. 2011;70(8):763–69. doi:10.1016/j.biopsych.2011.06.027.
   PubMed Web of Science ®Google Scholar
• Campolongo P, Trezza V, Cassano T, Gaetani S, Morgese MG, Ubaldi M, Soverchia L, Antonelli T, Ferraro L, Massi M, et al. Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addict Biol. 2007;12(3–4):485–95. doi:10.1111/j.1369-1600.2007.00074.x.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz J, Gomez M, Hernandez M, De Miguel R, Ramos JA. Cannabinoids and gene expression during brain development. Neurotox Res. 2004;6(5):389–401.
   PubMed Web of Science ®Google Scholar
• Aguado T, Carracedo A, Julien B, Velasco G, Milman G, Mechoulam R, Alvarez L, Guzman M, Galve-Roperh I. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biolog Chem. 2007;282(9):6854–62. doi:10.1074/jbc.M608900200.
   PubMed Web of Science ®Google Scholar
• Eljaschewitsch E, Witting A, Mawrin C, Lee T, Pm S, Wolf S, Hoertnagl H, Cs R, Schneider-Stock R, Nitsch R, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron. 2006;49(1):67–79. doi:10.1016/j.neuron.2005.11.027.
   PubMed Web of Science ®Google Scholar
• Paradisi A, Pasquariello N, Barcaroli D, Maccarrone M. Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. J Biolog Chem. 2008;283(10):6005–12. doi:10.1074/jbc.M707964200.
   PubMed Web of Science ®Google Scholar
• Hwang JY, Aromolaran KA, Zukin RS. The emerging field of epigenetics in neurodegeneration and neuroprotection. Nature Rev Neurosci. 2017;18(6):347–61. doi:10.1038/nrn.2017.46.
   PubMed Web of Science ®Google Scholar
• Simon RP. Epigenetic modulation of gene expression governs the brain’s response to injury. Neurosci Lett. 2016;625:16–19. doi:10.1016/j.neulet.2015.12.024.
   PubMed Web of Science ®Google Scholar
• Zhao CM, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132(4):645–60. doi:10.1016/j.cell.2008.01.033.
   PubMed Web of Science ®Google Scholar
• Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ, Zentar MP, Pollard S, Yanez-Munoz RJ, Williams G, et al. A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci. 2008;38(4):526–36. doi:10.1016/j.mcn.2008.05.001.
   PubMed Web of Science ®Google Scholar
• Galve-Roperh I, Aguado T, Rueda D, Velasco G, Guzman M. Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. Curr Pharm Des. 2006;12(18):2319–25.
   PubMed Web of Science ®Google Scholar
• Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest. 2005;115(11):3104–16. doi:10.1172/JCI25509.
   PubMed Web of Science ®Google Scholar
• Suliman NA, Taib CNM, Moklas MAM, Basir R. Delta-9-Tetrahydrocannabinol (a dagger(9)-THC) Induce neurogenesis and improve cognitive performances of male Sprague Dawley rats. Neurotox Res. 2018;33(2):402–11. doi:10.1007/s12640-017-9806-x.
   PubMed Web of Science ®Google Scholar
• Brown JP, Couillard-Despres S, Cooper-Kuhn CM, Winkler J, Aigner L, Kuhn HG. Transient expression of doublecortin during adult neurogenesis. J Comp Neurol. 2003;467(1):1–10. doi:10.1002/cne.10874.
   PubMed Web of Science ®Google Scholar
• Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen M, Weidner N, Bogdahn U, Winkler J, Kuhn HG, Aigner L. Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci. 2005;21(1):1–14. doi:10.1111/j.1460-9568.2004.03813.x.
   PubMed Web of Science ®Google Scholar
• Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. Can Med Assoc J. 2008;178(13):1669–78. doi:10.1503/cmaj.071178.
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–61. doi:10.1096/fj.07-9574LSF.
   PubMed Web of Science ®Google Scholar